KANEKA
19.1.2023 04:57:38 CET | Business Wire | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has decided to increase its GMP*1 manufacturing capacity for mRNA*2 in Kaneka Eurogentec S.A. (Headquarters: Liège, Belgium; President: Lieven Janssens), a wholly owned group company in Europe. We plan to start operation sequentially from the end of 2023 with a capital investment of 2 billion JPY and a production capacity that is around 5 times higher than the current capacity. Kaneka Eurogentec S.A. will grow as a leading company of biopharmaceutical CDMO*3, responding to the vigorous global demand for mRNA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118006042/en/
Kaneka Eurogentec S.A. building (Photo: Business Wire)
mRNA, which has been rapidly implemented in vaccines against COVID-19, is expected to be applied not only to vaccines for other infectious diseases but also to therapeutics for genetic diseases, cancer and so on. The demand for GMP manufacturing of mRNA will increase drastically with the active development of biopharmaceutical pipelines by pharmaceutical companies worldwide.
Kaneka Eurogentec S.A. is a CDMO for biopharmaceuticals inspected by the US FDA*4 and has world-class technology for producing plasmid DNA*5 and GMP manufacturing track records of over 25 years. They provide plasmid DNA, recombinant proteins, oligonucleotide*6 and so on as drug substances for pharmaceutical companies worldwide. In addition, Kaneka Eurogentec S.A. has started GMP manufacturing services for mRNA since 2020, and this capacity expansion will be utilized to expand the CDMO business.
Regarding the priority area of Health Care, Kaneka will continue to provide solutions globally for health issues through the growth of its biopharmaceutical business.
*1. |
GMP (Good Manufacturing Practice): A system for ensuring that products are consistently produced and controlled according to quality standards. |
*2. |
mRNA: An RNA molecule that is transcribed genetic information of protein synthesis from DNA. It is expected to be used as vaccines and therapeutics. |
*3. |
CDMO: Contract Development and Manufacturing Organization. |
*4. |
Food and Drug Administration (FDA): US governmental agency dealing with approval and supervision of violation of products which may be used by consumers in their daily life such as pharmaceutical products, cosmetics, medical devices, veterinary drugs and toys. |
*5. |
plasmid DNA: A general term for circular DNA molecules that exist outside the nucleus of bacteria such as E. coli and yeast, and that are passed down to daughter cells through cell division. |
|
It is conventionally used in processes for producing biopharmaceuticals such as therapeutic proteins and has been applied to genetic medicines and vaccines in recent years. |
*6. |
Oligonucleotide: Short polymeric sequences of nucleotides (RNA or DNA). It is used as drug substance of nucleic acid therapeutics. |
[General description of Kaneka Eurogentec S.A.]
Headquarters: Liège, Belgium
President: Lieven Janssens
Description of business: Manufacturing and sales of proteins, nucleic acids and peptides for medicinal, diagnostic and basic research uses
Established: 1985
Capital: 31 million euros
URL: http://www.eurogentec.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118006042/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DEWA International Launched as a Wholly Owned Independent Subsidiary of DEWA to Develop Global Energy and Water Projects9.7.2026 18:07:00 CEST | Press release
HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, announced the establishment of ‘DEWA International’, a wholly owned independent subsidiary of Dubai Electricity and Water Authority (DEWA). The company aims to develop conventional and clean energy projects worldwide and export Dubai’s successful energy and water infrastructure model to global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709099653/en/ DEWA International launched as a wholly owned independent subsidiary of DEWA to develop global energy and water projects (Photo: AETOSWire) HH Sheikh Ahmed bin Saeed Al Maktoum said: “Thanks to the vision and directives of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, Dubai has become a global model for achievement and accelerated development. Through its world-class infrastructure, particularly in the energy
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom